Patient‐Derived Organoids Can Guide Personalized‐Therapies for Patients with Advanced Breast Cancer

Abstract

Most breast cancers at an advanced stage exhibit an aggressive nature, and there is a lack of effective anticancer options. Herein, the development of patient-derived organoids (PDOs) is described as a real-time platform to explore the feasibility of tailored treatment for refractory breast cancers. PDOs are successfully generated from breast cancer tissues, including heavily treated specimens. The microtubule-targeting drug-sensitive response signatures of PDOs predict improved distant relapse-free survival for invasive breast cancers treated with adjuvant chemotherapy. It is further demonstrated that PDO pharmaco-phenotyping reflects the previous treatment responses of the corresponding patients. Finally, as clinical case studies, all patients who receive at least one drug predicate to be sensitive by PDOs achieve good responses. Altogether, the PDO model is developed as an effective platform for evaluating patient-specific drug sensitivity in vitro, which can guide personal treatment decisions for breast cancer patients at terminal stage.

Patient-derived microphysiological model identifies the therapeutic potential of metformin for thoracic aortic aneurysm

“…Beyond the traditional static 2D cell culture, microphysiological models are a high-content in vitro platform designed to reflect the key biological and biomechanical environment of cells residing in organs. 11 , 88 , 89 , 90 Numerous biomimetic devices have been developed to promote drug screening and physiological investigation. Huh et al described a 2D co-culture microsystem emulating lung alveoli for nanotoxicology studies 91 Similarly, using a 2D aortic smooth muscle-on-a-chip system, our previous work revealed that mitochondrial dynamics was involved in TAA caused by NOTCH1 insufficiency.…”

Precision-Cut Tumor Slices (PCTS) as an Ex Vivo Model in Immunotherapy Research

“…Nonetheless, both 2D and 3D cell line-based tumor models lack the in vivo tumor heterogeneity, where different cells within the same tumor site can have quite distinct and diverse genetic, epigenetic, phenotypic and tumor antigen expression profiles. To this end, the recent emergence of patient-derived organoids (PDOs) aims to predict patient response to chemotherapeutic, immunotherapeutic, and other targeted regimens across different cancer types (breast, lung, colorectal, gastrointestinal, and other cancers) [ 10 , 11 , 12 , 13 ]. PDOs are generated from patient solid tumor tissue, which is enzymatically digested to obtain tumor cells that are then cultured ex vivo in specialized basement membrane matrices allowing them to form 3D, tumor-resembling, organ-specific structures [ 14 ].…”

In vitro breast cancer models for studying mechanisms of resistance to endocrine therapy

“…As a living biobank, PDO models have the potential to be an effective platform for evaluating patient-specific drug sensitivity in vitro , which can prospectively guide treatment decisions for cancer patients at the terminal stage [ 61 ]. It also provides an alternative to reduce the use of animals in pre-clinical research [ 62 ].…”